📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: DalCor Pharmaceuticals

1.1 - Company Overview

DalCor Pharmaceuticals Logo

DalCor Pharmaceuticals

Headquarter: Canada
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of pharmacogenetic precision treatments for cardiovascular disease targeting patients with the ADCY9 AA genotype, including dalcetrapib; the completed Dal-GenE (DAL-301) cardiovascular outcomes trial; the Phase 3 Dal-GenE-2 (DAL-302) trial evaluating dalcetrapib’s potential to reduce fatal and non-fatal myocardial infarction; and the cobas ADCY9 genotype companion diagnostic developed with Roche Molecular Systems.

Products and services

  • Dalcetrapib: DalCor engineers a pharmacogenetic precision medicine designed to reduce cardiovascular risk in patients with the ADCY9 AA genotype
  • Dal-GenE-2 trial (DAL-302): A Phase 3 trial evaluating dalcetrapib's potential to reduce fatal and non-fatal myocardial infarction in patients with the ADCY9 AA genotype
  • Cobas ADCY9 genotype test: A companion diagnostic test developed with Roche Molecular Systems to identify patients with the ADCY9 AA genotype

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to DalCor Pharmaceuticals

VerAvanti Logo

VerAvanti

HQ: United States Website
  • Description: Provider of single-use intravascular endoscopic technologies, including a Scanning Fiber Endoscope delivering real-time, high-resolution images of intravascular anatomy to help diagnose and treat stroke and cardiovascular events; in-house MEMS manufacturing of micro-small components using precise robotics and cleanroom assembly; and O-pH imaging to measure oral biofilm acidity to predict and manage tooth decay.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full VerAvanti company profile →
Carmeda Logo

Carmeda

HQ: Sweden Website
  • Description: Provider of hemocompatible surface coating for medical devices.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Carmeda company profile →
Hoana Medical Logo

Hoana Medical

HQ: United States Website
  • Description: Provider of intelligent medical vigilance systems for healthcare.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Hoana Medical company profile →
CryoCath Logo

CryoCath

HQ: Canada Website
  • Description: Provider of cryoablation catheter systems for treating cardiac arrhythmias, tumors, and other obstructions, comprising flexible, steerable catheters supported by electromechanical consoles that deliver and recover refrigerants.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CryoCath company profile →
Corvidia Therapeutics Logo

Corvidia Therapeutics

HQ: United States Website
  • Description: Provider of clinical-stage research, development, and commercialization of transformative therapies for cardio-renal diseases, currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Corvidia Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for DalCor Pharmaceuticals

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to DalCor Pharmaceuticals

2.2 - Growth funds investing in similar companies to DalCor Pharmaceuticals

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for DalCor Pharmaceuticals

4.2 - Public trading comparable groups for DalCor Pharmaceuticals

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to DalCor Pharmaceuticals

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About DalCor Pharmaceuticals

What does DalCor Pharmaceuticals do?

DalCor Pharmaceuticals is a provider of pharmacogenetic precision treatments for cardiovascular disease targeting patients with the ADCY9 AA genotype, including dalcetrapib; the completed Dal-GenE (DAL-301) cardiovascular outcomes trial; the Phase 3 Dal-GenE-2 (DAL-302) trial evaluating dalcetrapib’s potential to reduce fatal and non-fatal myocardial infarction; and the cobas ADCY9 genotype companion diagnostic developed with Roche Molecular Systems.

Who are DalCor Pharmaceuticals's competitors?

DalCor Pharmaceuticals's competitors and similar companies include VerAvanti, Carmeda, Hoana Medical, CryoCath, and Corvidia Therapeutics.

Where is DalCor Pharmaceuticals headquartered?

DalCor Pharmaceuticals is headquartered in Canada.

How many employees does DalCor Pharmaceuticals have?

DalCor Pharmaceuticals has 1,000 employees 🔒.

When was DalCor Pharmaceuticals founded?

DalCor Pharmaceuticals was founded in 2010 🔒.

What sector and industry vertical is DalCor Pharmaceuticals in?

DalCor Pharmaceuticals is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for DalCor Pharmaceuticals

Who are the top strategic acquirers in DalCor Pharmaceuticals's sector and industry

Top strategic M&A buyers and acquirers in DalCor Pharmaceuticals's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for DalCor Pharmaceuticals?

Top strategic M&A buyers groups and sectors for DalCor Pharmaceuticals include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in DalCor Pharmaceuticals's sector and industry vertical

Which are the top PE firms investing in DalCor Pharmaceuticals's sector and industry vertical?

Top PE firms investing in DalCor Pharmaceuticals's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in DalCor Pharmaceuticals's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in DalCor Pharmaceuticals's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in DalCor Pharmaceuticals's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to DalCor Pharmaceuticals include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in DalCor Pharmaceuticals's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for DalCor Pharmaceuticals?

The key public trading comparables and valuation benchmarks for DalCor Pharmaceuticals include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for DalCor Pharmaceuticals for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for DalCor Pharmaceuticals with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in DalCor Pharmaceuticals's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for DalCor Pharmaceuticals with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in DalCor Pharmaceuticals's' sector and industry vertical?

Access recent funding rounds and capital raises in DalCor Pharmaceuticals's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for DalCor Pharmaceuticals